For Crohn’s Disease and Ulcerative Colitis, Company Reveals Results of New Study and Is Recruiting for Clinical Trial

For Crohn’s Disease and Ulcerative Colitis, Company Reveals Results of New Study and Is Recruiting for Clinical Trial
Immune Pharmaceuticals recently published new data on the impact of eotaxin-1 in ulcerative colitis (UC) and Crohn’s disease (CD). The article, “The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications,” was published in the journal Digestive Diseases and Sciences. Eotaxin-1 is a small protein that is involved in the recruitment of eosinophils (a type of white blood cells). The article presents the results of an observational clinical study characterizing serum and intestinal wall eotaxin-1 levels in inflammatory bowel disease (IBD) patients, and explores the effects of targeting eotaxin-1 by using specific antibodies in animal models. The study was led by Prof. Eran Goldin, chairman of the Digestive Diseases Institute at Shaare Zedek Medical Center in Jerusalem, an affiliate of Israel's Hebrew University School of Medicine in Israel, and partially suported by an Immune Pharmaceuticals’ unlimited grant. "The observational clinical study shows that tissue eotaxin-1 correlates with disease severity in both ulcerative colitis and Crohn’s disease," Goldin said in a press release. "Additionally, the classic DSS-mouse IBD model demonstrated that administration of anti-eotaxin-1 result
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *